Search Results
Your search for ,led matches 5950 pages
Showing 5301 - 5350Remembering Multiple Myeloma Patient Advocate Michael S. Katz, MBA
I first met Michael Katz, MBA, in 2004, 3 years after my brother, Dom, was diagnosed with multiple myeloma, and we were at a crossroads in his care and needed advice. Although an experimental regimen of thalidomide (Thalomid) and dexamethasone had successfully put Dom in remission for a year (the...
Learning to Communicate Science More Effectively
Alan Alda’s passion and appreciation for science extend nearly as far back to his early life as his love of acting. The son of actor Robert Alda, Mr. Alda began his acting career at the age of 16. Although he has appeared in such widely acclaimed films as The Seduction of Joe Tynan, Crimes and...
Living With a Rare Cancer—My Dr. Seuss World
No one ever expects to hear the words “you have cancer,” but over the course of the day, over 5,000 people in the United States are given that news.1 I first heard those words in the summer of 2007 and have been living with cancer ever since. At the time of my diagnosis, I knew this would forever...
A Less Is More View of Medicine
BOOKMARKTitle: Less Medicine, More Health: 7 Assumptions That Drive Too Much Medical CareAuthor: H. Gilbert Welch, MDPublisher: Beacon PressPublication date: March 3, 2015Price: $24.95; hardcover, 241 pages He’s the best physician that knows the worthlessness of most medicines. —Benjamin Franklin...
The Mechanisms Driving Cancer Pain
For over a decade, Patrick W. Mantyh, PhD, JD, has been investigating the molecular and cellular mechanisms that are involved in cancer-related pain, especially bone pain caused by advanced breast, prostate, and lung cancers. His early laboratory work using mouse models of bone cancer led to an...
In Search of Meaning: A Personal Journey
A famous Talmudic question asks: “What is truer than the truth?” The answer: “The story.” This is the story of my personal journey in search of meaning and the development of an approach to care for patients with advanced cancer, which I came to call “meaning-centered psychotherapy.” In terms of...
Ramucirumab With FOLFIRI in Metastatic Colorectal Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On April 24, the monoclonal antibody ramucirumab (Cyramza) was...
Mario R. Capecchi, PhD, Recognized With AACR Lifetime Achievement in Cancer Research Award
Mario R. Capecchi, PhD, was honored for his tremendous scientific contributions, which have had a profound impact on the understanding of cancer, with the 12th annual American Association for Cancer Research (AACR) Award for Lifetime Achievement in Cancer Research at the AACR Annual Meeting 2015....
Anti–PD-1 Antibody Pembrolizumab Improves Progression-Free and Overall Survival vs Ipilimumab in Advanced Melanoma
In the phase III KEYNOTE-006 trial reported in The New England Journal of Medicine,1 Caroline Robert, MD, PhD, Head of the Dermatology Unit at the Institut Gustave Roussy, Paris, and colleagues found that the anti–programmed cell death protein 1 (PD-1) antibody pembrolizumab (Keytruda) increased...
Potential Power of Meaning-Centered Group Psychotherapy in Patients With Advanced Cancer
The recent publication of the results of our National Cancer Institute (NCI) RO1-funded randomized controlled trial of meaning-centered group psychotherapy for advanced cancer patients in the Journal of Clinical Oncology,1 and the accompanying summary published in this issue of The ASCO Post,...
Welcome to Multikinase Inhibitors in Radioiodine-Refractory Thyroid Cancer
In the past 2 decades, the incidence of thyroid cancer has risen steeply, with rates now growing by 5.5% annually.1 In 2014, 62,980 new cases of thyroid cancer were diagnosed in the United States. The good news is that, overall, the prognosis of thyroid cancer remains excellent; 97.8% of patients...
Large Improvement in Progression-Free Survival With Lenvatinib in Radioiodine-Refractory Thyroid Cancer
In a phase III trial reported in The New England Journal of Medicine, Martin Schlumberger, MD, of Institut Gustave Roussy, and colleagues found that the multikinase inhibitor lenvatinib (Lenvima) produced a large improvement in progression-free survival vs placebo in patients with advanced...
Optimizing Treatment for Small, Lymph Node–Negative, HER2-Overexpressing Breast Cancers
Large, randomized phase III clinical trials showed that the addition of HER2-targeted therapy to chemotherapy for patients with early-stage, HER2-overexpressing breast cancers substantially decreased the risk of recurrence and improved survival. The chemotherapy given in these trials varied, but it ...
High Invasive Disease-Free Survival With Adjuvant Paclitaxel and Trastuzumab in Small, Node‑Negative, HER2-Positive Breast Cancers
In a phase II study reported in The New England Journal of Medicine, Sara M. Tolaney, MD, MPH, of Dana-Farber Cancer Institute, and colleagues found that adjuvant paclitaxel and trastuzumab (Herceptin) was associated with high invasive disease-free survival in women with small, node-negative,...
Taking the Next Step in a Storied Career
On March 31, 2015, Harold Varmus, MD, left his position as Director of the National Cancer Institute (NCI) to join the faculty of Weill Cornell Medical College in New York as its Lewis Thomas University Professor of Medicine. Dr. Varmus was also named Senior Associate Core Member of the New York...
MAINSAIL Trial: Worse Outcomes With Addition of Lenalidomide to Docetaxel-Prednisone in Prostate Cancer
The combination of docetaxel plus prednisone has been a standard therapy in advanced prostate cancer since 2004.1 Since then, there have been multiple randomized phase III trials comparing this standard of care with additional drug therapy. None has demonstrated improvement in outcome. Lenalidomide ...
Addition of Lenalidomide to Docetaxel-Prednisone Worsens Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
In the phase III MAINSAIL trial reported in The Lancet Oncology, Daniel P. Petrylak, MD, of Yale Cancer Center, New Haven, Connecticut, and colleagues found that the addition of lenalidomide (Revlimid) to docetaxel-prednisone in chemotherapy-naive men with metastatic castration-resistant prostate...
Stephen Grubbs, MD, to Lead ASCO’s New Clinical Affairs Department
Stephen S. Grubbs, MD, a community oncologist and Managing Partner at Medical Oncology Hematology Consultants, PA, has been named the Senior Director of ASCO’s new Clinical Affairs Department. Dr. Grubbs is a longtime ASCO member and volunteer and the Principal Investigator of the Delaware...
Prostate Cancer Survivorship: Identifying Opportunities for Improvement
Prostate cancer survivors currently approach 3 million in number and comprise 43% of all male cancer survivors in the United States.1 These men face myriad unique oncologic, functional, emotional, and psychological issues that require evaluation and management throughout the survivorship phase of...
Karen E. Knudsen, PhD, Named Director of Sidney Kimmel Cancer Center at Thomas Jefferson University
Karen E. Knudsen, PhD, has been named the Director of the Sidney Kimmel Cancer Center (SKCC) at Thomas Jefferson University and the Hilary Koprowski Chair of the Department of Cancer Biology of the Sidney Kimmel Medical College of Thomas Jefferson University. Dr. Knudsen has been serving in these...
PARP Inhibitors: The First Potential Treatment of Hereditary Ovarian Cancers
Poly(ADP-ribose) polymerase (PARP) inhibitors are one of the most exciting new classes of agents in development for the treatment of ovarian cancer. Olaparib (Lynparza), the lead oral PARP inhibitor, received accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of...
Illumination and Innovation: Transforming Data Into Learning
The ASCO Annual Meeting is our Society’s premier event and without a doubt one that is highly anticipated by the oncology world. The success of the meeting stems from the desire to share with each other our data and the knowledge we have gleaned from those data over the course of the past year. The ...
A Tribute to James F. Holland, MD, in Celebration of His 90th Birthday
Far and away the best prize that life has to offer is the chance to work hard at work worth doing. —Theodore Roosevelt Longevity, in and of itself, is not an accomplishment. Luck and good genes are just human lottery tickets. Most people fortunate enough to live long lives have a productive sweet ...
Andrew C. von Eschenbach, MD, Went From the Front Lines of Cancer Care to a Bird’s-Eye View of the Changing Oncology Landscape
At the end of the day, I’m still a kid from South Philly,” Andrew C. von Eschenbach, MD, former Director of the National Cancer Institute (NCI) and Commissioner of the U.S. Food and Drug Administration (FDA), told The ASCO Post. Dr. von Eschenbach is the product of a closely knit yet culturally...
Global Leader in Drug Development John L. Marshall, MD, Calls for a Smarter War on Cancer
John L. Marshall, MD, a global leader in the research and treatment of gastrointestinal cancers, grew up in Lexington, Kentucky, in a family that put high value on education. As a young boy, science was already on his mind; he enjoyed the explorative nature that chemistry and biology offered....
Nationally Recognized Leader in Myeloid Malignancies, Alan F. List, MD, Has High Hopes for the Future of Oncology
The Tampa Bay area of Florida is a haven for golfers and fishermen looking to unwind under the warm tropical skies. And the clean highways stretching through the scenic west coast of Florida are also a perfect excuse for weekend motorcycle enthusiasts, such as Alan F. List, MD, the President and...
Lymphoma Expert and Industry Leader Sandra J. Horning, MD, Pushes the Frontiers of Drug Development and Oncology Research
Due to childhood health issues, Sandra J. Horning, MD, formed an opinion about doctors at a young age: They were good people who helped other people. By her early teens, Dr. Horning began to ponder a career in medicine, which offered the possibility of blending her love of science with a career...
Bruce A. Chabner, MD, and His Innovative Pharmacology Research Led to the Development of Practice-Changing Therapies
Numerous challenges and milestones mark the course of an oncology career. Community doctors remember special patients, often speaking about a singular bond that is unique among a profession that deals with life and death daily. Researchers recount long hours of seeming futility and then the...
Carolyn R. ‘Bo’ Aldigé Reflects on 30 Years of Cancer Prevention
In 1985, Carolyn R. “Bo” Aldigé founded the Prevent Cancer Foundation in honor of her father, who had died the previous year of head and neck cancer. She started the Foundation in her kitchen with a typewriter, a sheath of carbon copy paper, and a telephone. “I quickly rented an office because a...
Incidence of Fractures Is ‘Compellingly Higher’ After Hematopoietic Stem Cell Transplantation
The incidence of fractures is “compellingly higher” after receiving hematopoietic stem cell transplantation, according to a retrospective study of patients receiving transplants for treatment of multiple myeloma, other hematologic malignancies, and some solid tumors (mostly breast and ovarian) as...
Alan C. Sartorelli, PhD, Pioneer in Targeted Chemotherapy and AACR Past President, Dies at Age 83
Alan C. Sartorelli, PhD, Alfred Gilman Professor of Pharmacology at Yale University School of Medicine, Past President of the American Association for Cancer Research (AACR), and a Fellow of the AACR Academy, died on April 30, 2015. A pioneer in cancer chemotherapy, Dr. Sartorelli was one of the...
Mount Sinai Receives $8.8 Million Grant to Further Stem Cell Research
An $8.8 million grant from the New York State Stem Cell Science Program (NYSTEM) will accelerate efforts by the Icahn School of Medicine at Mount Sinai to develop new stem cell-based treatments for chemotherapy-resistant blood cancer and other genetic blood disorders. Increasing Stem Cells...
How and When to Give Professional Feedback
Providing students and residents with feedback on their medical performance is a key element in their learning and development and ensures that high standards are met, according to Charlene M. Dewey, MD, MEd, FACP, Assistant Dean of Educator Development; Associate Professor of Medical Education and ...
Five Oncology Researchers Selected as Howard Hughes Medical Institute Investigators
The Howard Hughes Medical Institute announced 26 of the nation’s top biomedical researchers as investigators for the Institute. These scientists will receive the flexible support necessary to move their research in creative new directions. The initiative represents an investment in basic biomedical ...
Addition of Ramucirumab to Second-Line FOLFIRI Improves Overall Survival in Metastatic Colorectal Cancer
In the phase III RAISE trial reported in The Lancet Oncology, Josep Tabernero, MD, PhD, Head of Medical Oncology at Vall d’Hebron Institute of Oncology, Barcelona, and colleagues found that the addition of the antiangiogenic anti–vascular endothelial growth factor receptor 2 (VEGFR2) antibody...
ASCO 2015—Investigators Announce Patient Enrollment for NCI-MATCH Trial
Investigators for the nationwide trial, NCI-MATCH: Molecular Analysis for Therapy Choice (EAY131), have announced that the precision medicine trial will open to patient enrollment in July. The announcement was made recently during ASCO’s Annual Meeting in Chicago. The MATCH trial seeks to determine ...
Fulfilling NCI’s Commitment to Supporting the Best Science
On April 1, 2015, Douglas R. Lowy, MD, became Acting Director of the National Cancer Institute (NCI), succeeding Harold Varmus, MD, who left NCI to join the faculty of Weill Cornell Medical College in New York. (See “The Next Step in a Storied Career,” in the May 25, 2015 issue of The ASCO Post.)...
Nivolumab Increases Response Rate vs Chemotherapy in Advanced Melanoma Progressing After Anti–CTLA-4 Treatment
In a phase III trial (CheckMate 037) reported in The Lancet Oncology, Jeffrey S. Weber, MD, PhD, of the Moffitt Cancer Center, and colleagues found that treatment with the PD-1 (programmed cell death protein 1) inhibitor nivolumab (Opdivo) resulted in a significantly greater response rate vs...
Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman
Kenneth C. Frazier, JD, Chairman and CEO of Merck & Co., Inc., was elected Chairman of the Board of the Pharmaceutical Research and Manufacturers of America (PhRMA). Mr. Frazier formerly held the position of Chairman-Elect and succeeds Ian C. Read, Chairman and CEO of Pfizer, Inc. New Officers ...
New Studies Call for Smarter Approach to Prostate Cancer Screening
Prostate cancer is one of the most common cancers in American men, yet controversy over the utilization and frequency of prostate-specific antigen (PSA) screening methods remains, due to the overdiagnosis and overtreatment of men with low-grade, less-aggressive forms of the disease. At the 110th...
Cost Analysis of Bilateral Prophylactic Mastectomy
Bilateral prophylactic mastectomy may ease cancer-related anxiety for patients at high risk of breast cancer, but it does very little to contain the costs. A study presented at the American Society of Breast Surgeons 16th Annual Meeting found that bilateral prophylactic mastectomy was not...
Intensified Therapy Improves Survival in Wilms Tumor Patients With Rare Genetic Abnormality
Data from two phase III studies led by the Children’s Oncology Group show that augmenting or intensifying therapy for children with high-risk Wilms tumor improved relapse-free survival. These children are deemed to be at high risk due to a specific chromosomal abnormality that confers worse...
Deciphering the Genetic Variability of Cancer to Advance Precision Oncology Care
In 2014, Memorial Sloan Kettering Cancer Center (MSKCC) in New York opened the Marie-Josée and Henry R. Kravis Center for Molecular Oncology with the sole purpose of expediting the translation of novel molecular discoveries into clinical innovations to turn the goal of precision oncology care into...
Adjuvant Chemotherapy Proves Effective in Localized, High-Risk Prostate Cancer
For the first time, a large randomized trial has suggested that overall survival is improved by the addition of adjuvant chemotherapy to androgen suppression and radiotherapy in men with localized, high-risk, hormone-sensitive prostate cancer. Docetaxel has been used to treat metastatic...
Frederick Pei Li, MD, Pioneer of Cancer Genetics, Dies at 75
Frederick Pei Li, MD, who helped inaugurate the era of cancer genetics by demonstrating that people can inherit a genetic susceptibility to develop certain malignancies, died on June 12 at the age of 75. A Professor at Dana-Farber Cancer Institute, Harvard Medical School, and Harvard T.H. Chan...
Roberto Pili, MD, Expert in Prostate, Renal, and Bladder Cancers, Joins Indiana University Simon Cancer Center
Roberto Pili, MD, a nationally recognized expert in prostate, renal, and bladder cancers, has joined the Indiana University (IU) Melvin and Bren Simon Cancer Center. Dr. Pili is the Robert Wallace Miller Professor of Oncology at the Indiana University School of Medicine and Researcher at the IU...
Poliovirus for Glioblastoma Grabs National Attention
Researchers at The Preston Robert Tisch Brain Tumor Center at Duke University are being barraged by patients wishing to enroll in their clinical trial of an engineered poliovirus for recurrent glioblastoma. This comes as a result of a CBS 60 Minutes interview with lead researcher Matthias...
Ado-Trastuzumab Emtansine Fails to Replace Standard of Care in First-Line Metastatic Breast Cancer
Results are now in for the phase III MARIANNE trial. Although ado-trastuzumab emtansine (formerly known as T-DM1, Kadcyla) proved noninferior to trastuzumab (Herceptin) plus a taxane in the first-line metastatic breast cancer setting, it performed no better than the standard of care.1 “T-DM1 and...
How CancerLinQ™ Can Benefit People Living With Cancer
As a regular readers of The ASCO Post know, ASCO is developing an exciting new health information learning system called CancerLinQ™, which will exponentially enlarge our understanding of cancer therapy far beyond what we’ve achieved with our system of clinical trials. Cancer clinical trials have...
Irwin Rose, PhD, Nobel Laureate and Biochemist, Dies at 88
Scientist and Nobel Laureate Irwin “Ernie” Rose, PhD, passed away June 2, 2015, after a long illness. He was 88. Dr. Rose shared the 2004 Nobel Prize for chemistry with Aaron Ciechanover, MD, DSc, and Avram Hershko, MD, PhD, of the Israel Institute of Technology for their pioneering work in...
